Structure

InChI Key DHMTURDWPRKSOA-RUZDIDTESA-N
Smile NC(=O)N1CCC(CC(=O)N2CCC([C@H]3c4ncc(Br)cc4CCc4cc(Cl)cc(Br)c43)CC2)CC1
InChI
InChI=1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C27H31Br2ClN4O2
Molecular Weight 638.83
AlogP 5.91
Hydrogen Bond Acceptor 3.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 3.0
Polar Surface Area 79.53
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 36.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Protein farnesyltransferase inhibitor PubMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Transferase
100 2-1900 - - 100
Other cytosolic protein
- 70 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Progeria 4 D011371 FDA
Neoplasm Metastasis 3 D009362 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 3 D002289 ClinicalTrials
Myelodysplastic Syndromes 3 D009190 ClinicalTrials
Leukemia, Myelomonocytic, Chronic 3 D015477 ClinicalTrials
Hepatitis D 3 D003699 ClinicalTrials
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 D015464 ClinicalTrials
Ovarian Neoplasms 2 D010051 ClinicalTrials
Urinary Bladder Neoplasms 2 D001749 ClinicalTrials
Liver Neoplasms 2 D008113 ClinicalTrials
Urethral Neoplasms 2 D014523 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Astrocytoma 1 D001254 ClinicalTrials
Colorectal Neoplasms 1 D015179 ClinicalTrials
Head and Neck Neoplasms 1 D006258 ClinicalTrials
Central Nervous System Neoplasms 1 D016543 ClinicalTrials
Gliosarcoma 1 D018316 ClinicalTrials
Lymphoma 1 D008223 ClinicalTrials

Related Entries

Scaffolds

Cross References

Resources Reference
CAS NUMBER 193275-84-2
ChEBI 47097
ChEMBL CHEMBL298734
DrugBank DB06448
EPA CompTox DTXSID90172927
FDA SRS IOW153004F
Guide to Pharmacology 8024
PDB 336
PharmGKB PA166129466
PubChem 148195
SureChEMBL SCHEMBL19032
ZINC ZINC000003950115